---
title: "Assistant Director, Adult Cystic Fibrosis Center"
canonical_url: "https://itif.org/person/bruce-c-trapnell/"
---

# Bruce C. Trapnell
**Assistant Director, Adult Cystic Fibrosis Center**

Bruce Trapnell, MS, MD received his medical degree from the University of Maryland in 1985, and completed a medical residency at The Ohio State University Hospitals and a fellowship in pulmonary medicine at the Clinical Center of the National Institutes of health, where he then served as Senior Attending Physician. Subsequently, he established the Division of Pulmonary and Virology Studies at Genetic Therapy, Inc., a subsidiary of Novartis, Pharma, serving as Vice President before joining Cincinnati Children’s Hospital Medical Center, where he is now Full Professor.Dr. Trapnell has conducted lung disease research since his training and has been continuously funded by the NIH since 2001, shortly after his arrival in Cincinnati. He has published over 90 original articles and has trained more than 16 post-doctoral fellows. Dr. Trapnell’s research interests are focused to the pathogenesis and therapy of rare lung diseases and mechanisms by which GM-CSF regulates innate immunity and lung host defense.Dr. Trapnell is Director of Cincinnati’s Cystic Fibrosis Therapeutics Development Network Center, Assistant Director of the Adult Cystic Fibrosis Care Center, Director of the Rare Lung Diseases Clinical Research Consortium, Scientific Director of the Pulmonary Alveolar Proteinosis Foundation. Dr. Trapnell is the past Scientific Director of the Alpha-1 Foundation, for which he organized and directed the grant program for eight years.

Bruce Trapnell, MS, MD received his medical degree from the University of Maryland in 1985, and completed a medical residency at The Ohio State University Hospitals and a fellowship in pulmonary medicine at the Clinical Center of the National Institutes of health, where he then served as Senior Attending Physician. Subsequently, he established the Division of Pulmonary and Virology Studies at Genetic Therapy, Inc., a subsidiary of Novartis, Pharma, serving as Vice President before joining Cincinnati Children’s Hospital Medical Center, where he is now Full Professor.

Dr. Trapnell has conducted lung disease research since his training and has been continuously funded by the NIH since 2001, shortly after his arrival in Cincinnati. He has published over 90 original articles and has trained more than 16 post-doctoral fellows. Dr. Trapnell’s research interests are focused to the pathogenesis and therapy of rare lung diseases and mechanisms by which GM-CSF regulates innate immunity and lung host defense.

Dr. Trapnell is Director of Cincinnati’s Cystic Fibrosis Therapeutics Development Network Center, Assistant Director of the Adult Cystic Fibrosis Care Center, Director of the Rare Lung Diseases Clinical Research Consortium, Scientific Director of the Pulmonary Alveolar Proteinosis Foundation. Dr. Trapnell is the past Scientific Director of the Alpha-1 Foundation, for which he organized and directed the grant program for eight years.

---
*Source: Information Technology & Innovation Foundation (ITIF)*
*URL: https://itif.org/person/bruce-c-trapnell/*